Pharmacology and Clinical Pharmacy Research最新文献

{"title":"Evaluating the Knowledge, Attitude, and Perception of Medical Interns regarding Contraception in a Tertiary Care Centre","authors":"Usha NS, Sabari Anandh J V, Afzal Khan A K, Swapna R Nayaka","doi":"10.15416/pcpr.v8i1.39227","DOIUrl":"https://doi.org/10.15416/pcpr.v8i1.39227","url":null,"abstract":"Maternal mortality is one of the significant burdens requiring appropriate measures including family planning methods to control post-partum morbidity and mortality. The early age of marriage among women is accompanied by early pregnancies also contributes to maternal mortality. Knowledge about contraceptive usage could prevent such incidences. This study aimed to evaluate the knowledge, attitude, and perception regarding contraceptives among medical interns in our college. This cross-sectional questionnaire study was done on 60 house surgeons (interns), at MVJ Medical College and Research Hospital, Hoskote, using a validated questionnaire that consisted of 22 questions including MCQs and case scenarios to assess their knowledge, perception, and attitude about contraceptive methods. Data were analyzed in the form of percentages. Among 60 interns, 36 were females and the majority of students were from urban backgrounds. About 73.3% of interns had adequate knowledge about various contraceptive methods and their usage. The interns have a perception that illiteracy, lack of awareness and social, and religious values are major hurdles for contraceptive usage and have an attitude that doctors are most suitable to give information regarding contraceptive methods. Considering medical interns as future physicians and their responsible role in counseling about contraceptive usage in effective family planning, they need to have a positive attitude with fair knowledge and perception about the contraceptive methods which can be achieved by educating them early in their academic carrier.","PeriodicalId":32814,"journal":{"name":"Pharmacology and Clinical Pharmacy Research","volume":"285 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135792062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of ADRs with Hypokalaemia for Severity, Preventability and Causality in a Tertiary Care Centre in South India","authors":"Shiva Murthy Nanjundappa, Safeera Alikutty K, Mabel Kuriakose EV, Basalingappa Shivanna","doi":"10.15416/pcpr.v8i1.38913","DOIUrl":"https://doi.org/10.15416/pcpr.v8i1.38913","url":null,"abstract":"Hypokalemia is one of the most frequently seen electrolyte disturbances in clinical practice. Various drugs are known to induce hypokalemia, such as furosemide, thiazides, dicloxacillin, ampicillin, etc. The objective of this study is to assess hypokalemia adverse drug reactions (ADRs) for severity, preventability, and causality in a tertiary care centre in the southern part of India. It is a retrospective, cross-sectional study. Data collected at DMWIMS Medical College, India, as per the ongoing pharmacovigilance program of India from November 1st, 2016 to October 30th, 2017 (12 month period) was included for analysis in this study. The SADR form published by the Government of India under the PVPI program was used for collecting the data. In-patients who were on at least one medication and experienced hypokalemia ADR with or without other symptoms or signs were included. Both primary suspected drugs and concomitantly prescribed drugs were analyzed. For the assessment of ADRs, modified Hartwig and Siegel assessment scales and plasma K+ level criteria were used for severity, Schumock and Thornton criteria for preventability, the WHO-UMC scale, and Naranjo's algorithm for causality, respectively. Sixty hypokalemia ADRs were considered for analysis. Both genders were equally affected, with a mean age of 64.28 ± 3.02 years. Four groups of drugs were suspected to cause hypokalemia viz., anti-asthmatics (36.67 %), diuretics (31.67 %), antibiotics (18.33 %), and antidiabetics (13.33 Polypharmacy was reported in 43.33% of cases, with 4.40 ± 01.689 drugs prescribed on average. To summarize, hypokalemia is a preventable ADR and minor variations in serum K+ levels can have a negative impact on patients' outcomes and mortality. FDC of Levosalbutamol with Ipratropium Bromide was the most common causative agent suspected of causing hypokalemia. Elderly patients receiving one or more drugs that are known to alter K+ levels, need close monitoring, and correction of hypokalemia should be done to improve prognosis. Further studies are required to understand the mechanisms involved in DDIs and DDiIs to derive preventive strategies.","PeriodicalId":32814,"journal":{"name":"Pharmacology and Clinical Pharmacy Research","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136047710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modifiable Comorbidity as a Risk Factor for DRPs and Unimproved NIHSS Score in Ischemic Stroke Patients","authors":"Firdha A. Wardhani","doi":"10.15416/pcpr.v8i1.38919","DOIUrl":"https://doi.org/10.15416/pcpr.v8i1.38919","url":null,"abstract":"Drug-related problems are a common problem among stroke patients due to comorbidities resulting from the complex management of stroke treatment leading to polypharmacy management. Studies show that 90% of stroke patients have drug-related problems (DRPs). However, there is limited information on the impact of comorbidities as risk factors for DRP prevalence and unfavorable prognosis in patients with ischemic stroke. The objective of this investigation was to determine whether risk factors for DRP and clinical outcomes as modifiable comorbidities in ischemic stroke patients admitted to a tertiary hospital between January 2020 and October 2021 were indeed significant influences. The study was conducted retrospectively using a cross-sectional analysis of patient's medical records. The study found no significant association between the presence of comorbidities and polypharmacy in patients with the incidence of DRP, although we found that the DRPs occurrence was found more in a patient with comorbidities and polypharmacy. Diabetes mellitus was found to have a significant association with no improvement in NIHSS scores in ischemic stroke patients. We found that diabetes mellitus patient had an increased risk of non-improvement NIHSS score 2,987 times compared to patients without diabetes mellitus. The second increased risk was the presence of comorbid hypertension (OR 1.352), the third was the occurrence of polypharmacy (OR 1,175), and the fourth was dyslipidemia (OR 1.138).","PeriodicalId":32814,"journal":{"name":"Pharmacology and Clinical Pharmacy Research","volume":"18 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136047711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Study on the Occurrence of Hand Dermatitis in Healthcare Workers during the COVID-19 Pandemic due to Enhanced Hand Hygiene","authors":"Abhishree BS, Kavitha R, Geetha A","doi":"10.15416/pcpr.v8i1.38851","DOIUrl":"https://doi.org/10.15416/pcpr.v8i1.38851","url":null,"abstract":"Hand hygiene measures have increased in the general population and amongst the health care workers since the outbreak of the pandemic. However, enhanced hand hygiene can have an adverse effect on the skin barrier leading to the development of hand dermatitis. The aim of the study was to determine the occurrence of occupational-related contact dermatitis among the health care workers. An observational, questionnaire based cross-sectional study was conducted in 2021 amongst HCWs of a tertiary care hospital. The data were analysed using Microsoft Excel for Windows. The frequency of hand washing had increased to > 5 times in 42% of the HCWs while hand sanitizer usage had increased to >5 times in 95% of them during the pandemic. The duration of glove usage had increased from 3% pre-pandemic to 91 % during the pandemic and majority of them used latex gloves. Symptoms of hand dermatitis in HCWs had increased from 3% pre-pandemic to 84% during the pandemic. Less than 10 % of the study participants moisturised their hands after sanitization. The fact that over 84% of the HCWs developing HD during the pandemic can be attributed to preventive measures to reduce the transmission of the virus. Measures such as use of moisturizers should be recommended to prevent the onset of occupational hand eczema. It is thus imperative to raise awareness of HD in India and intensive measures should be provided.","PeriodicalId":32814,"journal":{"name":"Pharmacology and Clinical Pharmacy Research","volume":"28 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136328425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Efficacy and Safety of Adding Olanzapine to Triple Drugs Regimen to Prevent Chemotherapy-induced Nausea and Vomiting: A systematic Review and Meta-analysis of RCTs","authors":"S. Hiremath, S. Devendrappa","doi":"10.15416/pcpr.v7i2.37936","DOIUrl":"https://doi.org/10.15416/pcpr.v7i2.37936","url":null,"abstract":"Chemotherapy-induced nausea and vomiting (CINV) is a complication of highly emetogenic chemotherapy (HEC) agents. The present meta-analysis was conducted to quantify and analyze the efficacy and safety of adding olanzapine to a Neurokinin Receptor Antagonist (NKRA) based triple-drug regimen in preventing HEC-induced CINV. Electronic database searches in PUBMED and Cochrane library was conducted using MeSH search terms “olanzapine” and “chemotherapy-induced nausea and vomiting.” Randomized or cross-over trials comparing the efficacy of “olanzapine + NKRA based triple-drug regimen” vs. “placebo + NKRA based triple-drug regimen” in patients of age > 18 years with any malignancy receiving HEC were considered under inclusion criteria. Complete Response (CR) for the delayed (25–120 h) phase of CINV in patients receiving HEC agents was the primary outcome measure analyzed. Outcome measures were estimated by calculating the Risk Difference (RD) values and their 95% Confidence Intervals (CI). The Mantel-Haenszel method and both fixed and random effect models were used in the analysis by Revman 5.4.1 soft- ware. An additional 14% (RD: 0.14, 95% CI: 0.09 to 0.19) of patients treated with olanzapine + triple-drug regimen had a statistically significant higher CR in the delayed phase when compared to placebo + NKRA-based triple-drug regimen. Adding olanzapine at 10mg to the triple-drug regimen significantly improves delayed phase CR rates by 16% and delayed phase ‘no significant nausea’ rates by 30%. Results need to be interpreted cautiously in the background of response variations and limited trials included in our analysis","PeriodicalId":32814,"journal":{"name":"Pharmacology and Clinical Pharmacy Research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47300243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Variation in Response to Pharmacological Intervention with Risperidone and the Role of Adjuvant Medications in the Treatment of Autism Spectrum Disorders: A Systematic Review and Meta-analysis","authors":"S. Hiremath, S. Devendrappa","doi":"10.15416/pcpr.v7i2.38401","DOIUrl":"https://doi.org/10.15416/pcpr.v7i2.38401","url":null,"abstract":"Non-genetic traits as predictors of variation in response to pharmacological interventions in ASD need to be identified for better management. This review aims to identify these non-genetic traits and the role of adjuvant medications in ASD. Electronic database searches in PUBMED and Cochrane libraries were conducted using MeSH search terms \"Autism\" and \"Risperidone.\" Randomized or cross-over trials comparing the efficacy of ‘risperidone plus placebo’ vs. ‘risperidone plus adjuvant medications’ using Aberrant Behavior Checklist-Community Version (ABC-CV) scores in ASD patients of any age group were included in the analysis. The quantity of reduced irritability (ABC-I) sub-score was the primary outcome measure analyzed.In contrast, the reduction in remaining ABC-CV sub-scores at the end of 10 weeks were the secondary outcome measures analyzed. All the outcome measures were estimated by calculating the Mean Difference (MD) values and their 95% Confidence Intervals (CI) by both fixed and random effect models using Revman 5.4.1 software. A total of 13 trials were found to be eligible and included in the quantitative synthesis of efficacy. A small but significant decrease in the ABC irritability sub-score was evident in the ‘risperidone plus adjuvants’ group (MD: -3.19, 95% CI:-3.82, -2.56, N=658). The meta-analysis results attributed the highest decrease in ABC-irritability sub-scores to adjuvant topiramate. There is a possibility of bias and minimal impact of adjuvants in alleviating irritability symptoms of ASD. Baseline severity of irritability symptoms and the dose/medication regimen appear to be possible non-genetic traits responsible for variation in response to pharmacological intervention.","PeriodicalId":32814,"journal":{"name":"Pharmacology and Clinical Pharmacy Research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47952270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating Anti-diabetic Effects of Autoclaved Curcuma longa Linn (turmeric) Extracts using Mouse Tissues in vitro","authors":"Abeer F. R. Alanazi, Esra'a AL-Omari, A. Naser, Norah M. Algahtani, Jim McFarlane","doi":"10.15416/pcpr.v7i2.38706","DOIUrl":"https://doi.org/10.15416/pcpr.v7i2.38706","url":null,"abstract":"Curcumin, the active compound found in turmeric, is believed to delay the development of diabetes through several mechanisms. This study aimed to investigate if an aqueous extract of turmeric can improve glucose uptake and uric acid in mouse tissues in vitro, after inclusion of turmeric in the diet for four weeks. Fourteen adult male Swiss mice were divided into three groups. The first group was the control (n=6) that was given clean water, the second group of mice (n=4) was given 5% autoclaved turmeric extract in drinking water, and the third group (n=4) was given 5% non-autoclaved turmeric extract in drinking water. After four weeks, the cardiac muscle, skeletal muscle, pancreas, and liver tissues were dissected and used for analysis.  The results showed that the aqueous 5% turmeric extract reduced glucose in cardiac tissues while the plasma glucose was not changed. Cardiac muscle, liver, pancreas, and skeletal muscle showed glucose absorption after the 5% turmeric treatment. This research shows that turmeric did improve glucose uptake in most tissues, although it was not significant due to the limitations of this study. Tissues may need to be cultured longer and media processed quicker to prevent evaporation. Turmeric continues to show great potential in the treatment of type 2 diabetes and may present an alternative way of treating diabetes.","PeriodicalId":32814,"journal":{"name":"Pharmacology and Clinical Pharmacy Research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41647897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Study of Cost-effectiveness and Safety of 0.2% Olopatadine in Comparison with Combination of 0.1% Olopatadine and 0.4% Ketorolac Eye Drops in Vernal Keratoconjunctivitis among Rural Population","authors":"Adhiti Todime, Narendar Koyagura, Krisna C. Pasula, Prasanna Vedula, Baswaraj Munge, P. Patnaik","doi":"10.15416/pcpr.v7i2.37692","DOIUrl":"https://doi.org/10.15416/pcpr.v7i2.37692","url":null,"abstract":"The study aimed to compare the cost-effectiveness and safety of 0.2% Olopatadine with a combination of 0.1% Olopatadine and 0.4% Ketorolac eye drops in Vernal keratoconjunctivitis (VKC) among the rural population. This was a randomized, open-label, prospective study conducted on 129 patients who were diagnosed with VKC. All the patients were randomly allotted to 2 treatment groups. Group 1 received 0.2% Olopatadine eye drops/single drops/three times a day. Group 2 treated with a combination of 0.1% Olopatadine and 0.4% Ketorolac eye drops/single drops/two times a day for four weeks. The patients were advised to follow up during the study period in the second and fourth weeks. During the follow-ups, post-intervention cure rate, adverse drug reactions (ADR) monitoring, and cost-effectiveness of both the drugs were evaluated. A statistically significant (p<0.05) reduction of clinical symptoms was observed in both groups after four weeks of treatment. In 0.2% Olopatadine intervention, 9 cases of ADR were reported out of the 62 patients. Furthermore, treatment with a combination of 0.1% Olopatadine and 0.4% Ketorolac has shown 12 cases from 58 having ADR. Our study revealed that the 0.2% Olopatadine eye drops were a comparatively affordable choice since the cost was less. Therefore, 0.2% Olopatadine is considered a better drug choice in the given scenario of the rural population regarding their safety and cost-effectiveness. ","PeriodicalId":32814,"journal":{"name":"Pharmacology and Clinical Pharmacy Research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47582347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost Variation Study of Various Brands of Oral Fluoroquinolones Available in India: An Economic Perspective","authors":"Pallav Hetawal, Sapna A. More, K. Gupta, P. Mishra","doi":"10.15416/pcpr.v7i2.37669","DOIUrl":"https://doi.org/10.15416/pcpr.v7i2.37669","url":null,"abstract":"Fluoroquinolones are broad-spectrum antibacterial for treating respiratory tract, intra-abdominal, urinary tract, pelvic, joint, bone, soft tissue, and skin infections. The economic burden on patients affects compliance in developing countries like India. Therefore, the prices of drugs should be controlled effectively. Hence, this study was done to assess the cost variation of branded oral fluoroquinolones available in India compared with generic counterparts. The maximum and minimum cost of oral fluoroquinolones (INR per 10 tablets) of the same strength and dosage form manufactured by different companies was obtained from Drug Today April to July 2021 Volume 1, MIMS, and 1mg.com. The cost ratio and the percentage cost variation of individual drug brands were calculated. Prices of generic fluoroquinolones from the Jan Aushadhi scheme (JAS) were compared with branded drugs. Of 11 different oral fluoroquinolones, levofloxacin 500 mg had the highest percentage variation of 11.100%, and three formulations marketed by a few manufacturers have a percentage reduction of less than 100%. Of 23 different combinations available as 33 different dosages, the highest cost variations were observed in Norfloxacin 400 mg plus tinidazole 600 mg combination (1317%). When compared, some generic fluoroquinolones available under JAS were not cheaper than the minimum cost of their branded counterparts. Wide variation in the cost of the different brands of the same oral fluoroquinolones manufactured by other companies was observed. This adds to the economic burden for the patients. Hence, stakeholders should aim to decrease the cost variation among different brands while maintaining therapeutic efficacy ","PeriodicalId":32814,"journal":{"name":"Pharmacology and Clinical Pharmacy Research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47588201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Warfarin Use in Cardiac Clinic Outpatients","authors":"N. Putriana, T. Rusdiana, T. Rostinawati, M. R. Akbar, D. Destiani","doi":"10.15416/pcpr.v7i1.39666","DOIUrl":"https://doi.org/10.15416/pcpr.v7i1.39666","url":null,"abstract":"The use of warfarin was monitored using the International Normalized Ratio (INR) value. This study aims to determine the relationship between the patient’s demographic variables and INR, as well as the therapy result and differences in their INR value. A cross-sectional study was used with retrospective observational data collected by tracing secondary information of medical records from outpatients with heart disease on warfarin therapy at Dr. Hasan Sadikin hospital Bandung between 2016 to 2020. Subsequently, the difference in patients’ INR value was analyzed with the Mann-Whitney test based on dosage. At the same time, the relationship between demographic variables and INR was examined using the Chi-square test and Spearman correlation. The INR examination results in 192 subjects showed 124 patients (64.6%) reached the target with an average value of 2.37 ± 0.21 and a warfarin dose of 19.31 ± 6.25 mg weekly, while 68 (35.4%) had an average of 1.82 ± 0.73 and a dose of 20.24 ± 6.24 mg weekly. Subsequently, the difference test with Mann Whitney (p = 0.004) showed a variation in the INR value based on the warfarin dose. The Spearman correlation analysis results indicated a relationship between BMI (p = 0.009), daily (0.010), and weekly dose (0.008) on the INR value with the correlation coefficient of 0.188; 0.186; and 0.192;  indicating a negative association with very weak correlation strength. This study showed that a majority of patients reached the INR value of 2-3, and the demographic variables associated with this ratio were BMI and warfarin dose. The decision to increase and decrease the warfarin dose is determined by INR value and BMI.","PeriodicalId":32814,"journal":{"name":"Pharmacology and Clinical Pharmacy Research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45024211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}